Sequence analysis of known antibiotic resistance genes of the Mycobacterium tuberculosis complex (MTBC) is increasingly being used to infer phenotypic resistance to a variety of antibiotics. However, a clear understanding of the genotype -phenotype relationship is required to interpret genotypic susceptibility results accurately. In this context, it is particularly important to distinguish phylogenetically informative neutral polymorphisms from true resistance-conferring mutations.
Introduction
An estimated 450 000 cases of multidrug-resistant tuberculosis (MDR TB; resistant to at least rifampicin and isoniazid) occurred worldwide in 2012, of which 9.6% were extensively drug resistant (XDR; defined by additional resistance to a fluoroquinolone and at least one injectable drug). 1 Efforts to contain drug-resistant TB depend on rapid detection and effective treatment of cases together with public health interventions to prevent and investigate ongoing transmission.
2 However, traditional phenotypic drug susceptibility testing (DST) is slow, technically demanding and unreliable in some cases. 3 As a result, genotypic alternatives for DST have been developed. Current genotypic assays can only interrogate short stretches of DNA, but can be applied directly to clinical samples. For example, the Cepheid Xpert MTB/RIF can detect the Mycobacterium tuberculosis complex (MTBC) and rifampicin resistance in 2 h directly from sputum. 4 By contrast, whole-genome sequencing requires an initial culture and is not in routine use yet, but is theoretically capable of detecting resistance to all antibiotics simultaneously in addition to providing the ultimate molecular resolution for epidemiological investigations. 2, 5 A precise understanding of the genetic diversity of MTBC is required in order to interpret the results of genotypic DST assays. 6 In this context, it is particularly important to distinguish single-nucleotide polymorphisms (SNPs) that are merely polymorphisms in resistance-mediating genes from mutations that actually confer resistance. For example, the T202A mutation in thyA (Rv2764c) was initially implicated in para-aminosalicylic acid resistance, but later shown to be merely a marker for the Latin American -Mediterranean genotype. 7 -9 Similarly, mutations in Rv2629 were mistaken for rifampicin resistance mutations. 10 -14 Once uncovered, these polymorphisms have to be taken into consideration when designing targeted molecular assays that rely on hybridization to detect resistance mutations. 6 Indeed, for the recent development of an assay to detect fluoroquinolone resistance additional probes had to be included in order to compensate for the non-synonymous S95T change in gyrA (Rv0006) that is not related to antibiotic resistance. 6, 15 Finally, elucidating the diversity within antibiotic resistance genes in phylogenetically diverse strain collections is important in the detection of intrinsic antibiotic resistance.
6 Using this approach, we have recently raised the possibility that Mycobacterium canettii might be intrinsically resistant to PA-824, 16 which is currently in Phase 2 clinical trials. In the light of the fact that M. canettii is also intrinsically resistant to pyrazinamide, the proposed three-drug regimen of PA-824, moxifloxacin and pyrazinamide might not be effective in treating infections caused by this species. 6, 16, 17 Using a collection of 71 strains that encompasses all major MTBC genotypes, we therefore set out to map the genetic diversity in 18 genes that are known to be involved or were previously implicated in antibiotic resistance to eight current as well as two novel antibiotics (a summary of the role of each of these resistance genes can be found in the supplement of our recent study of XDR TB 2 ). This included bedaquiline [previously known as TMC-207 or R207910; atpE (Rv1305)], capreomycin [tlyA (Rv1694)], ethambutol [embC (Rv3793), embA (Rv3794) and embB (Rv3795)], fluoroquinolones (gyrA), isoniazid [inhA (Rv1484), katG (Rv1908c) and ahpC (Rv2428)], PA-824 [fgd1 (Rv0407) and ddn (Rv3547)], para-aminosalicylic acid (thyA), prothionamide [mshA (Rv0486) and inhA (Rv1484)], rifampicin [rpoB (Rv0667) and Rv2629, which had been erroneously proposed as a novel resistance gene 11 -14 ] and streptomycin [rpsL (Rv0682), rrs (MTB000019) and gidB (Rv3919c)]. For completeness, we also included data from one of our prior studies that focused on two of the three known pyrazinamide resistance genes [rpsA (Rv1630) and pncA (Rv2043c)]. 17 
Materials and methods

Mycobacterial strains
Seventy-one MTBC strains from a reference collection comprising all major phylogenetic lineages were included in this study. Apart from some exceptions, we included three clinical, not clonally related strains for each of the following genotypes: M. tuberculosis Haarlem, Latin AmericanMediterranean (LAM), Beijing (n ¼ 6), Delhi/Central Asian (CAS), East African Indian (EAI), Uganda I and II, Ghana, Cameroon, Turkey (Tur), Feuerriegel et al. Phylogenetic SNPs in resistance genes Table S1 for detailed strain information, available as Supplementary data at JAC Online).
The remaining methods, including growth conditions, drug susceptibility testing, molecular strain typing and DNA isolation, PCR and sequencing (primers and conditions are listed in Table S2 , available as Supplementary data at JAC Online) are available as Supplementary data at JAC Online.
Results and discussion
In this study we mapped the genetic diversity in 18 genes that are known to be involved or were previously implicated in antibiotic resistance to eight current as well as two novel antibiotics in order to uncover polymorphisms that were not associated with antibiotic resistance but were phylogenetically informative markers for specific MTBC genotypes. We also included data from one of our prior studies that focused on two of the three known pyrazinamide resistance genes (rpsA and pncA).
17
We identified a total of 121 different changes relative to the H37Rv reference (43 synonymous, 68 non-synonymous and 8 intergenic SNPs, as well as two insertions). Fifty-eight of these mutations (25 synonymous, 28 non-synonymous and 4 intergenic SNPs and 1 insertion) were phylogenetically informative markers for single genotypes (Tables 1 -3) . Moreover, we found a number of mutations that were more deeply rooted within the phylogeny of MTBC and therefore differentiated larger groups (e.g. phylogenetically modern from ancient lineages). In fact, it was possible to differentiate most MTBC genotypes with these phylogenetically informative changes, with the exception of the M. tuberculosis genotypes Cameroon, New-1 and S-type, as illustrated in Figure 1 . Finally, we identified 63 further mutations, including known resistance mutations that occurred in a genotype-independent manner and did therefore not appear to be phylogenetically informative (Table S3 , available as Supplementary data at JAC Online).
Importantly, no new genotypic evidence of intrinsic antibiotic resistance that was shared by one or more genotypes of MTBC was uncovered. For example, the M. tuberculosis genotypes New-1, Ural and Tur, which we had not included in our earlier study of PA-824 susceptibility, 16 did not share any non-synonymous mutations in either fgd1 or ddn. As a result, the only known instances of intrinsic antibiotic resistance within our collection involve pyrazinamide in M. bovis (due to the pncA H57D mutation 17 ) and M. canettii, although the genetic basis for its intrinsic pyrazinamide resistance remains unclear [we had previously suggested that mutations in rpsA might be responsible, 17 but recently changes in panD (Rv3601c) have emerged as an alternative 18 ]. Similarly, the mechanism for the elevated MICs and the potential intrinsic resistance of M. canettii to PA-824 remained uncertain, despite the fact that we detected some novel mutations in fgd1 in two M. canettii strains that we had not found in our earlier study. 16 atpE, which encodes the target of bedaquiline, the first representative of a novel class of anti-TB drugs to be approved by the US FDA in 40 years, was fully conserved in our phylogenetically diverse collection of MTBC isolates, with the exception of a Figure 1 . Maximum parsimony tree (500 bootstraps) rooted in M. canettii based on the phylogenetically informative mutations identified in this study. Genes and amino acid positions or nucleotide positions, discriminating single genotypes or groups of genotypes, are exemplarily shown in red (a full list can be found in Table 1 ). Some SNPs were found to be specific for deeper branches in the phylogeny, defining larger groups, such as clade 1 strains (highlighted in green) or strains of the Euro-American lineage (highlighted in blue). An asterisk indicates a bootstrap value of 100%.
Phylogenetic SNPs in resistance genes 1209 JAC Downloaded from https://academic.oup.com/jac/article-abstract/69/5/1205/683928 by guest on 22 November 2018 synonymous mutation in codon 69 that was shared by all M. africanum West African II strains. This genotype is generally restricted to West Africa, where it is responsible for up to half of human pulmonary TB cases. 19 This observation confirmed prior studies that had found this mutation to be a marker for this genotype. 19 This finding is relevant for the genotypic detection of resistance to bedaquiline, given that the known atpE resistance mutations span codons 28 -66. 20 To detect these mutations with a hybridization test, akin to the Hain GenoType or the Cepheid Xpert, the synonymous A96A mutation would therefore not have to be compensated for (i.e. provided that probes were relatively short, they could be designed without having to overlap the synonymous mutation). 6 In summary, this study represents one of the most extensive analyses of the genetic diversity in major resistance genes in MTBC to date. The polymorphisms detected will allow researchers to interpret genotypic susceptibility data with greater accuracy. Moreover, these data might guide the development of targeted hybridization assays 6 and are needed for the valid interpretation of next-generation sequencing-based approaches for the detection of resistance mutations in clinical MTBC isolates.
